menu
    • menu
    [{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Mylan","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Mylan"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mapi Pharma \/ PRA Health Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ PRA Health Sciences"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"MHC class II gene","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mapi Pharma \/ Mapi Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Mapi Pharma \/ Mapi Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Mapi Pharma

    Menu

    Mapi Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Viatris

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment ...

                            Details : Copaxone Depot, a long-acting glatiramer acetate designed to be administered as an intramuscular injection, is being investigated as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis (RMS).

                            Brand Name : WhisperJECT

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 07, 2023

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Viatris

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing Forms of Multiple ...

                            Details : The study evaluating a long-acting glatiramer acetate (copaxone) injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 percent compared to placebo.

                            Brand Name : Copaxone

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2022

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mapi Pharma to Present Posters on GA Depot for Treating Relapsing Forms of Multiple Sclerosis (MS) and Primary...

                            Details : At AAN, company will be presenting 5 year data from Phase IIa study in RRMS. Also, the results seeN in the ongoing Phase II study for GA Depot in primary progressive MS (PPMS) patients, to be presented at the meeting as plan to initiate a Phase-3 for PPM...

                            Brand Name : GA Depot

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 31, 2022

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressi...

                            Details : GA Depot is a long-acting injection version of the approved Copaxone® (Glatiramer Acetate) designed to be administered as an intramuscular injection once every four weeks, is being evaluated for treatment of relapsing forms of multiple sclerosis.

                            Brand Name : Copaxone

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 30, 2022

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : PRA Health Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mapi Pharma Engages PRA Health Sciences as CRO for Phase III Multiple Sclerosis Trial

                            Details : GA Depot is a long-acting version of Teva Pharmaceutical’s Copaxone (glatiramer acetate). Mapi Pharma is working with the CRO PRA Health Sciences for its Phase III trial investigating glatiramer acetate depot (GA Depot) for relapsing forms of multiple ...

                            Brand Name : Copaxone

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 20, 2021

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : PRA Health Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial

                            Details : GA Depot is a long acting injection version of the approved Glatiramer Acetate products (Copaxone® and its generic versions) for treating multiple sclerosis (RMS), designed to be administered as an intramuscular injection once every four weeks.

                            Brand Name : GA Depot

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 21, 2020

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Viatris

                            Deal Size : $20.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Mapi Pharma, Mylan Expand MS Alliance

                            Details : Pharma announced an additional investment from Mylan in support of continued Phase 3 clinical study progress to bring to market in the U.S. Glatiramer Acetate Depot for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 15, 2020

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Viatris

                            Deal Size : $20.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth